tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Hold Rating for Jazz Pharmaceuticals Amid Balanced Risk-Reward and Competitive Challenges
PremiumRatingsHold Rating for Jazz Pharmaceuticals Amid Balanced Risk-Reward and Competitive Challenges
25d ago
Zymeworks price target raised to $40 from $30 at Stifel
Premium
The Fly
Zymeworks price target raised to $40 from $30 at Stifel
1M ago
Strong Buy Rating for Jazz Pharmaceuticals Driven by Promising Ziihera Drug and Positive Market Outlook
Premium
Ratings
Strong Buy Rating for Jazz Pharmaceuticals Driven by Promising Ziihera Drug and Positive Market Outlook
1M ago
Jazz Pharmaceuticals’ Promising Pipeline and Strong Trial Results Lead to Buy Rating and Raised Price Objective
PremiumRatingsJazz Pharmaceuticals’ Promising Pipeline and Strong Trial Results Lead to Buy Rating and Raised Price Objective
1M ago
Zymeworks Stock (ZYME) Soars on Positive Results for Cancer Drug Ziihera, Top Analysts Boost Price Targets
Premium
Market News
Zymeworks Stock (ZYME) Soars on Positive Results for Cancer Drug Ziihera, Top Analysts Boost Price Targets
1M ago
Jazz Pharmaceuticals price target raised to $225 from $185 at Jefferies
Premium
The Fly
Jazz Pharmaceuticals price target raised to $225 from $185 at Jefferies
1M ago
Jazz Pharmaceuticals price target raised to $205 from $185 at Morgan Stanley
PremiumThe FlyJazz Pharmaceuticals price target raised to $205 from $185 at Morgan Stanley
1M ago
Jazz Pharmaceuticals rises 20.8%
Premium
The Fly
Jazz Pharmaceuticals rises 20.8%
1M ago
Jazz Pharmaceuticals Stock Surges on Positive Phase 3 Trial Results
Premium
Market News
Jazz Pharmaceuticals Stock Surges on Positive Phase 3 Trial Results
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100